Table 3.
Selected studies of autologous and allogeneic HSCT for ENKL patients.
| HSCT |
Study design |
No. | First-line therapy | Disease stage | Mid. follow-up, month | OS% | PFS% | TRM% |
|---|---|---|---|---|---|---|---|---|
| Autologous HSCT | Retrospective (99) | 62 | Noneanthracycline-based n = 51 (82%) |
Localized (n = 31) Advanced (n = 31) |
43 | 68 (3y) 52 (3y) |
65 (3y) 40 (3y) |
3.2 |
| Retrospective (36) | 28 | Asparaginase-containing n = 6 (21%) |
Localized (n = 16) Advanced (n = 10) Unknown (n = 2) |
33 | 52 (2y) | 41 (2y) | 11* (1y) 22* (2y) |
|
| Prospective (100) | 80 | Asparaginase-containing n = 80 |
Autologous HSCT (n = 20) Controls (n = 60) |
80 | 79 vs. 52%, p = 0.026 (5y) | NA | 0 | |
| Allogeneic HSCT | Retrospective (101) | 18 | SMILE (78%) | Localized (n = 5) Advanced (n = 13) |
21 | 57 (5y) | 51 (5y) | 22 |
| Retrospective (102) | 82 | SMILE (15%) | Localized (n = 35) Advanced (n = 22) Unknown (n = 25) |
36 | 34 (3y) | 28 (3y) | 30* | |
| Retrospective (103) | 12 | NA | Advanced (n = 12) | 16 | 55 (3y) | 53 (3y#) | 8.3 |
HSCT, hematopoietic stem cell transplantation; Mid, median; TRM, transplantation - related mortality;
*
NRM, non-relapse Mortality; NA, not available;
#
EFS, event-free survival.